153 related articles for article (PubMed ID: 37940696)
1. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
[TBL] [Abstract][Full Text] [Related]
2. LMS-Based Pediatric Reference Values for Parameters of Phosphate Homeostasis in the HARP Cohort.
Pott V; Tietze H; Kanzelmeyer N; von der Born J; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
J Clin Endocrinol Metab; 2024 Feb; 109(3):668-679. PubMed ID: 37850343
[TBL] [Abstract][Full Text] [Related]
3. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
5. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
[TBL] [Abstract][Full Text] [Related]
6. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.
Hofbauer LC; Schoppet M; Schüller P; Viereck V; Christ M
Clin Endocrinol (Oxf); 2004 Feb; 60(2):214-9. PubMed ID: 14725683
[TBL] [Abstract][Full Text] [Related]
8. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
Kulik-Rechberger B; Kozłowska M
J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
[TBL] [Abstract][Full Text] [Related]
10. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
11. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
12. The relationship between chemerin, bone metabolism, the RANKL/RANK/OPG system, and bone mineral density in girls with anorexia nervosa.
Ostrowska Z; Morawiecka-Pietrzak M; Pluskiewicz W; Świętochowska E; Strzelczyk J; Gołąbek K; Gaździcka J; Ziora K
Endokrynol Pol; 2022; 73(1):26-34. PubMed ID: 35119086
[TBL] [Abstract][Full Text] [Related]
13. TGF-β1, bone metabolism, osteoprotegerin, and soluble receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Strzelczyk J; Gołąbek K; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2016; 67(5):493-500. PubMed ID: 27828689
[TBL] [Abstract][Full Text] [Related]
14. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
[TBL] [Abstract][Full Text] [Related]
15. Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Wołkowska-Pokrywa K
Postepy Hig Med Dosw (Online); 2012 Sep; 66():655-62. PubMed ID: 23001207
[TBL] [Abstract][Full Text] [Related]
16. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein.
Sennels HP; Jacobsen S; Jensen T; Hansen MS; Ostergaard M; Nielsen HJ; Sørensen S
Scand J Clin Lab Invest; 2007; 67(8):821-35. PubMed ID: 17852826
[TBL] [Abstract][Full Text] [Related]
17. Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.
Erazmus M; Rumińska M; Witkowska-Sędek E; Kucharska AM; Stelmaszczyk-Emmel A; Majcher A; Pyrżak B
Front Endocrinol (Lausanne); 2022; 13():963467. PubMed ID: 36060948
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
19. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
